R.I.Y. Lieverse

Halilaj, I., Ankolekar, A., Lenaers, A., Chatterjee, A., Oberije, C. J. G., Eppings, L., Smit, H. J. M., Hendriks, L. E. L., Jochems, A., Lieverse, R. I. Y., van Timmeren, J. E., Wind, A., & Lambin, P. (2024). Improving shared decision making for lung cancer treatment by developing and validating an open-source web based patient decision aid for stage I-II non-small cell lung cancer. Frontiers in Digital Health, 5, Article 1303261. https://doi.org/10.3389/fdgth.2023.1303261

Van Limbergen, E. J., Hoeben, A., Lieverse, R. I. Y., Houben, R., Overhof, C., Postma, A., Zindler, J., Verhelst, F., Dubois, L. J., De Ruysscher, D., Troost, E. G. C., & Lambin, P. (2021). Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study. International Journal of Radiation Oncology Biology Physics, 109(5), 1421-1430. https://doi.org/10.1016/j.ijrobp.2020.11.053

Marcus, D., Lieverse, R. I. Y., Klein, C., Abdollahi, A., Lambin, P., Dubois, L. J., & Yaromina, A. (2021). Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. Cancers, 13(6), Article 1468. https://doi.org/10.3390/cancers13061468

Olivo Pimentel, V., Marcus, D., van der Wiel, A. M., Lieuwes, N. G., Biemans, R., Lieverse, R. I., Neri, D., Theys, J., Yaromina, A., Dubois, L. J., & Lambin, P. (2021). Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. Journal for ImmunoTherapy of Cancer, 9(3), Article 001764. https://doi.org/10.1136/jitc-2020-001764

Lieverse, R. I. Y., Marcus, D., van der Wiel, A. M. A., Van Limbergen, E. J., Theys, J., Yaromina, A., Lambin, P., & Dubois, L. J. (2020). Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Molecular oncology, 14(7), 1555-1568. https://doi.org/10.1002/1878-0261.12705

Lieverse, R. I. Y., Van Limbergen, E. J., Oberije, C. J. G., Troost, E. G. C., Hadrup, S. R., Dingemans, A.-M. C., Hendriks, L. E. L., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., de Jong, M. C., Bussink, J., Geets, X., Valentini, V., Elia, G., Neri, D., Billiet, C., Abdollahi, A., ... Lambin, P. (2020). Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 20(1), Article 557. https://doi.org/10.1186/s12885-020-07055-1

Sanduleanu, S., van der Wiel, A. M. A., Lieverse, R. I. Y., Marcus, D., Ibrahim, A., Primakov, S., Wu, G., Theys, J., Yaromina, A., Dubois, L. J., & Lambin, P. (2020). Hypoxia PET Imaging with [18F]-HX4-A Promising Next-Generation Tracer. Cancers, 12(5), Article 1322. https://doi.org/10.3390/cancers12051322

Lambin, P., Lieverse, R. I. Y., Eckert, F., Marcus, D., Oberije, C., van der Wiel, A. M. A., Guha, C., Dubois, L. J., & Deasy, J. O. (2020). Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy. Seminars in Radiation Oncology, 30(2), 187-193. https://doi.org/10.1016/j.semradonc.2019.12.003

Rogers, W., Seetha, S. T., Refaee, T. A. G., Lieverse, R. I. Y., Granzier, R. W. Y., Ibrahim, A., Keek, S. A., Sanduleanu, S., Primakov, S. P., Beuque, M. P. L., Marcus, D., van der Wiel, A. M. A., Zerka, F., Oberije, C. J. G., van Timmeren, J. E., Woodruff, H. C., & Lambin, P. (2020). Radiomics: from qualitative to quantitative imaging. British Journal of Radiology, 93(1108), Article 20190948. https://doi.org/10.1259/bjr.20190948

Lambin, P., Lieverse, R., Baumann, M., & Ebert, N. (2019). Will immunotherapy really change radiotherapy? Lancet oncology, 20(12), 1642-1644. https://doi.org/10.1016/S1470-2045(19)30682-5